Stockreport

Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial

Bellicum Pharmaceuticals, Inc.  (BLCM) 
Last bellicum pharmaceuticals, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.bellicum.com/investor-overview
PDF Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo-cel in BP-004 European registrational trial Investigational trial resul [Read more]